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Background
Allergic rhinitis (AR) is poorly controlled. Treated patients,
even those on multiple therapies still experience symptoms.
In a UK survey, 70.5% of moderate-to-severe AR patients
took ≥2 medications (either Rx or over the counter) in an
attempt to achieve better and faster symptom relief.
Aim
To explore the extent of co-prescribing by UK general
practitioners (GPs) during the hay-fever season in patients
with seasonal AR (SAR), perennial AR (PAR), and comor-
bid asthma.
Method
A retrospective database study using the Optimum Patient
Care Research Database consisting of data extracted from
GP records supplemented with patient-reported outcomes
from questionnaires. Patients included in the analysis had
a recorded AR diagnosis and ≥1 AR therapy scripts during
1st March 2010 to 31st August 2010.
Results
In all, 22,381 AR patients were included. Results are
summarized in the table.
Conclusion
In contrast to previous surveys, these data relate to pre-
scriptions only and show a high level of co-prescribing
behavior among UK GPs. There was a significant shift to
combination therapy during the season, particularly for
PAR patients, with strong co-prescription evident regard-
less of asthma co-morbidity. These data indicate that
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Table 1
1st March 2010 to 31st August 2010
SAR (n=16187) PAR (n=6194)
Therapy, n (%) Season Start Season End Season Start Season End
Single therapy 10776 (65.5) 8850 (54.7) 4764 (76.9) 2974 (48.0)
Dual therapy 3782 (23.4) 5213 (32.2) 1172 (18.9) 2445 (39.5)
Triple therapy 1615 (10.0) 2062 (12.7) 244 (3.9) 694 (11.2)
Quadruple therapy 24 (0.1) 62 (0.4) 14 (0.2) 77 (1.2)
5 therapies 0 (0.0) 0 (0.0) 0 (0.0) 4 (0.1)
Total on combinations 5421 (33.5) 7337 (45.3) 1430 (23.0) 3220 (52.0)
Season End, n (%) Asthma (n=8787) Non Asthma (n=13594)
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(i) UK GPs are aware that current therapy provides insuf-
ficient symptom relief, (ii) that AR is a costly disease
to treat requiring several GP visits over the season
for therapy modification and (iii) there is a need for an AR
therapy which provides more complete symptom relief.
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